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Background: Tulbaghia violacea Harv. (Alliaceae) is used to treat various ailments, including hypertension (HTN) in
South Africa. This study aims to evaluate the contributions of muscarinic receptors and changes in plasma
aldosterone levels to its anti-hypertensive effect.
Methods: In the acute experiments, methanol leaf extracts (MLE) of T. violacea (30–120 mg/kg), muscarine (0.16
-10 μg/kg), and atropine (0.02 - 20.48 mg/kg), and/or the vehicle (dimethylsulfoxide (DMSO) and normal saline (NS))
were respectively and randomly administered intravenously in a group of spontaneously hypertensive (SHR)
weighing 300 to 350 g and aged less than 5 months. Subsequently, T. violacea (60 mg/kg) or muscarine (2.5 μg/kg)
was infused into eight SHRs, 20 min after atropine (5.12 mg/kg) pre-treatment. In the chronic (21 days) experiments,
the SHRs were randomly divided into three groups, and given the vehicle (0.2 ml/day of DMSO and NS), T. violacea
(60 mg/kg/day) and captopril (10 mg/kg/day) respectively into the peritoneum, to investigate their effects on blood
pressure (BP), heart rate (HR), and plasma aldosterone levels. Systolic BP and HR were measured using tail-cuff
plethysmography during the intervention. BP and HR were measured via a pressure transducer connecting the
femoral artery and the Powerlab at the end of each intervention in the acute experiment; and on day 22 in the
chronic experiment.
Results: In the acute experiments, T. violacea, muscarine, and atropine significantly (p < 0.05) reduced BP
dose-dependently. T. violacea and muscarine produced dose-dependent decreases in HR, while the effect of
atropine on HR varied. After atropine pre-treatment, dose-dependent increases in BP and HR were observed with
T. violacea; while the BP and HR effects of muscarine were nullified. In the chronic experiments, the T. violacea-
treated and captropril-treated groups had signicantly lower levels of aldosterone in plasma when compared to
vehicle-treated group. Compared to the vehicle-treated group, significant reduction in BP was only seen in the
captopril-treated group; while no difference in HR was observed among the groups.
Conclusion: The results obtained in this study suggest that stimulation of the muscarinic receptors and a reduction
in plasma aldosterone levels contribute to the anti-hypertesive effect of T. violacea.
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Globally, sixty per cent of the burden of cardiovascular
disease (CVD) and about fifty percent of that of coron-
ary heart disease (CHD) is due to hypertension (HTN).
Furthermore, in developing countries, a rapid increase
in CVD which mirrors the global trend of rapid
urbanization is seen [1], and the overall burden of CVD
has been predicted to rise by approximately 150% in
these countries in the next 20 years [2]. This may be
partly due to a decline in deaths in infancy, childhood,
and adolescence from infections [1]. In Africa, CVD
affects 1.3 million people yearly [3,4]; and Africans [5]
and African Americans [6,7] respond with heightened
vascular reactivity when exposed to stress. The preven-
tion and treatment of risk factors for CVD are effective
and sustainable, but poverty and cultural factors hinder
the implementation of the DASH (Dietary Approaches to
Stop Hypertension) [1,8,9] found to be very effective in
African-Americans [10]. Furthermore, developing coun-
tries, particularly those in sub-Saharan Africa are finan-
cially unable to intervene in all the risk factors for CVD
[8,9], necessitating a continuous search for better and
cheaper alternate methods for controlling blood pressure
(BP) [11].
Africa has a high rate of endemism of medicinal plants
[12,13] which are used by rural communities to treat
various ailments, including HTN [14-17]. Tulbaghia
violacea (T. violacea), an example of these plants [18-20]
has attracted a lot of interest in the scientific community
of late [20-23]. In the field of cardiovascular research, T.
violacea has been reported to reduce blood pressure in
spontaneously hypertensive rats (SHR) [21], normoten-
sive Wistar rats [23] and Dahl salt sensitive (DSS) rats
[24], which were associated with inhibition of the β1 adre-
noceptors [21], inhibition of the angiotensin I converting
enzyme (ACE) [21,23], and decreased renal angiotensin II
type 1 (AT1) receptor gene expression [24]. Raji, Mugabo
et al., [21] also reported a reduction in heart rate (HR)
with T. violacea. Consequently, the present study will in-
vestigate possible contributions of muscarinic receptors to
the acute anti-hypertensive effect of T. violacea, and also
investigate the effect of chronic administration of T. viola-
cea or captopril on BP, HR, plasma aldosterone levels, and
body weight in the SHR.Methods
Plant material
Fresh plants were purchased from the New Plant Nursery,
George, South Africa in August and September, 2008;
identified by the taxonomist at the Department of Bio-
diversity and Conservation Biology of the University of
the Western Cape (UWC), Bellville; and deposited at
the herbarium with voucher numbers 6955 and 6956.Plant extraction
Fresh leaves weighing 2.4 kg were washed, and dried in
an oven at 30°C until a constant mass was obtained.
Dried leaves were ground into powder. Methanol leaf ex-
tract (MLE) was prepared by Soxhlet extraction and the
excess solvent removed at 40°C using a rotavapor. The
dried black paste obtained was placed in a −20°C freezer
before being dried further using a freeze-drier. The final
dried extract (76.6 g or 3.2% yield) was stored in a
brown bottle in a refrigerator at −4°C. Fresh MLE was
dissolved with drops of dimethylsulfoxide (DMSO) and
the required concentration made up with 0.9% normal
saline and filtered before infusion into the rat to prevent
the formation of emboli.
Animals
Healthy male SHR weighing 300–350 g, aged less than
5 months old were obtained from the Animal Unit at
the University of Cape Town, South Africa; and were
kept under laboratory conditions in the animal room,
School of Pharmacy, UWC; and given water and feed ad
libitum. Room temperature was kept at 24°C, with a
12:12-h light–dark cycle.
Drugs
Atropine (atropine sulfate salt monohydrate), muscarine
((+)-muscarine chloride) and captopril were purchased
from Sigma-Aldrich, South Africa. Solvents were 0.9%
saline (Adcock Ingram, South Africa) and dimethylsulf-
oxide (DMSO, Merck Chemicals, South Africa). Atro-
pine and muscarine were dissolved in 0.9% saline, while
T. violacea and captopril were initially dissolved with
drops of DMSO, and made up to the required dilution
(concentration) using 0.9% saline. Fresh drug solutions
were prepared at the beginning of each experiment and
kept on ice during the course of the experiment.
In- vivo experiments
Rats were anaesthetized with 6% sodium pentobarbitone
(Kyron Laboratories, South Africa) at a dose of 40 mg/
kg intraperitoneally, and fastened in a supine position
on a heated rat-operating table (BioScience), whose
temperature was maintained at 37.3 ± 0.5°C by a thermo-
stat. A temperature probe (AD Instruments) was inserted
into the rectum to monitor the body temperature. The tra-
chea was cannulated to maintain airflow during the experi-
ment and an oxygen mask placed close to the opening of
the tracheal cannula to maintain adequate supply of oxygen
(Afrox, South Africa) to the rat. The right external jugular
vein was cannulated with a small polyethylene cannula to
allow intravenous infusion of drugs via a syringe placed on
the two-way injection Ascor AP 22 syringe pump (Poland).
The left femoral artery was cannulated with a small poly-
ethylene cannula filled with heparin (Intramed, South
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was connected to a BP transducer attached to a BP ampli-
fier (ADInstruments, Australia) and Power Lab 4/20 T
(ADInstruments, Australia) for recordings of the BP and
HR onto a Chart 5.0 for Windows software (ADInstru-
ments, Australia). Rats were allowed a 15-min stabilization
period to ensure that BP and HR parameters were stable
before any further experiment, and each group consisted of
8 rats. Drugs were infused, flushed with 0.1 ml of normal
saline and results recorded within 3 min of infusion. Pres-
sures and HR were allowed to return to baseline values
(10–15 min) before further doses were infused.
Tail-cuff plethysmography
In conscious SHR, systolic BP was measured using non-
invasive tail-cuff plethysmography (ADInstruments, Australia),
between 09:00 and 16:00 h. The SHRs were warmed at 37°C
for 10 min and allowed to rest in a glass restrainer, and a
black conical plastic piece with a nose opening, placed over
the head region of the rat, to cover the eyes of the rat, and
consequently allow the rat to rest better; before the tail-cuff
plethysmography. An average of 5 consecutive readings was
recorded. Rats were trained every 3 days for BP measure-
ment for two weeks prior to the start of the actual experi-
ment [26-29].
Experimental protocol
a) Muscarinic receptors20
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FigDose–response experiments (DRE) for muscarine (0.16
-10 μg/kg) and atropine (0.02 - 20.48 mg/kg) were
performed in the SHR. The dose at which 80% of the
maximum effect obtained was noted.
Previously [21], 80% of the maximum effect of T.
violacea, was achieved at 60 mg/kg. Therefore, this
dose (60 mg/kg), half of it (30 mg/kg), and twice this
dose (120 mg/kg) were used in this study. T. violacea
(30, 60 and 120 mg/kg) was infused into eight SHRs
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pre-treated with atropine (5.12 mg/kg). In this study,
T. violacea or muscarine was infused 20 min [30-33]
after atropine was infused into rats. T. violacea (30,
60 and 120 mg/kg) was then infused, with the BP
and HR values allowed to return to baseline, prior to
the subsequent dose of the MLE being administered.
b)T. violacea effect compared with muscarine chloride
after atropine pre-treatment.
Eight SHRs were pre-treated with atropine (5.12 mg/
kg), before T. violacea (60 mg/kg) was infused into
these rats. The BP and HR returned to baseline,
before muscarine (2.5 μg/kg) was infused into the
same rat.
The effects of the MLE and the standard drugs on
SBP, DBP, MAP and HR were evaluated.
c) Body weight, BP, HR and plasma aldosterone levels
The SHRs used in this protocol were allowed 14 days
of acclimatization to the restrainers [26-29]. The
body weight, SBP and HR of the rats were measured
on the first day of study, and the rats were randomly
divided into three groups of eight each. The
intraperitoneal injection given to the rats during the
next 21 days were T. violacea (60 mg/kg), captopril
(10 mg/kg) or 0.2 mls of the vehicle (DMSO + NS).
The BP and HR of the rats were measured using the
non-invasive tail cuff plethysmography during the
intervention period. On day 22, invasive BP
measurement was done, and blood was collected
from the femoral artery of the SHR after the BP and
HR values had stabilized and recorded. Blood was
stored in ethylenediaminetetraacetic acid (EDTA)
tubes and rapidly spun at 10 000 rpm, in a centrifuge
to separate the plasma from the blood cells. The
plasma obtained was then stored in another set of
EDTA tubes and placed in a – 40°C freezer. Plasma
samples were sent to the Veterinary Hormone
Laboratory, Faculty of Veterinary Science, University
of Pretoria (South Africa), for analysis of plasma
aldosterone levels.2:17 2:18
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Figure 2 Dose-response graph of the effect of muscarine (0.2 – 10.0 µg/kg) on BP and HR. Values are presented as mean ± SEM.
* Indicates statistical significance.
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The paired and/or unpaired Student’s T test was used to
calculate statistical significance (p < 0.05), using the
Microsoft Excel software.
Ethical considerations
The methodology and ethics adhered to in this study
were approved by the Ethics Committee of the Univer-
sity of the Western Cape, and the registration number
obtained was 09/7/35. All experimental procedures used
in this study were conducted in accordance with the
guidelines provided by the European Community guide-
lines (EEC Directive of 1986; 86/609/EEC).20091
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Figure 3 Effect of atropine (5.12 mg/kg) on BP in a SHR. Chart scalingResults
Effect of (+)-muscarine chloride on BP and HR in SHR
In a dose-dependent fashion, muscarine (0.2 – 10.0 μg/kg)
significantly reduced the SBP, DBP and MAP. The reduc-
tions in HR were only significant at the two highest doses
(Figures 1 and 2).Effect of atropine on BP and HR in SHR
In a dose-dependent fashion, atropine (0.02 - 20.48 mg/kg)
significantly reduced the SBP, DBP, and MAP. The
changes in HR with atropine were not dose-dependent
(Figures 3 and 4).0 atropine
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Figure 4 Dose-response graph of the effect of atropine (0.02 – 20.48 mg/kg) on BP and HR. Values are presented as mean ± SEM.
* Indicates statistical significance.
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T. violacea (30, 60 and 120 mg/kg) significantly reduced
the SBP, DBP, MAP and HR in a dose-dependent man-
ner (Figure 3).
Effect of T. violacea on BP and HR, after pre-treatment
with atropine
Simultaneous co-infusion of atropine (5.12 mg/kg) with
T. violacea (60 mg/kg) produced BP changes in the rats
similar to those obtained with the infusion of the
MLE alone (results not shown here). However, the in-
fusion T. violacea, 20 min after pre-treatment of the
rats with atropine (5.12 mg/kg), led to dose-dependent
increases in the BP and HR of the rats (Figures 7 and 8),
as opposed to the hypotensive effect previously seen
with the infusion of doses of T. violacea alone (Figures 5
and 6). The BP increases were significant at all doses,B
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Figure 5 Effect of T. violacea (60 mg/kg) on BP in a SHR. Chart scalingbut the HR increases was only significant at the highest
dose (Figure 8).Comparing T. violacea with (+)-muscarine chloride
As, above, the infusion of T. violacea (60 mg/kg) in rats
pre-treated with atropine (5.12 mg/kg) produced signifi-
cant increases in SBP and MAP (Figure 10), but the BP
and HR effects of muscarine (2.5 μg/kg) (Figures 1 and 2)
were nullified (Figures 9 and 10).Effect of chronic administration of the vehicle, T. violacea
or captopril on body weight
Intraperitoneal administration of the vehicle (DMSO + NS),
T. violacea (60 mg/kg/day) or captopril (10 mg/kg/day) for
21 days did not produce any significant change in the mean
body weight of any of the SHR groups (Figure 11).Time (sec)
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Figure 6 Effect of T. violacea (30, 60 and 120 mg/kg) on BP (a) and HR (b). PP is pulse pressure. Values are presented as mean ± SEM.
* Indicates statistical significance.
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or captopril on blood pressure
The SBP values obtained using the invasive BP measure
technique were significantly lower on day 22 when com-
pared to the values obtained using the non-invasive tail
cuff technique on day 1, in all groups. These reductions
in SBP were most significant in the captopril group,
while the reduction in SBP in T. violacea group was
similar to that of the control group. Significant reduc-
tions in HR also occurred in the control and captopril
groups (result not shown here). After 21 days, significant
lower SBP, DBP or MAP values were only seen in the
captopril group when compared with the control group.
There was no significant difference in final HR among
the groups (Figure 12).B
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Figure 7 Effect of T. violacea (60 mg/kg) on BP, after atropine pre-treEffect of chronic administration of the vehicle, T. violacea
or captopril on plasma aldosterone level
Compared to the plasma aldosterone levels (1319.5 ±
76.7 pg/ml) in the control group significantly lower
values of 740.2 ± 65.0 pg/ml and 838.4 ± 77.9 pg/ml were
observed in the T. violacea and captopril treated groups
respectively (Figure 13).
Discussion
Muscarinic receptors
In the present study, both muscarine and atropine pro-
duced reductions in BP (Figures 1,2,3 and 4). While mus-
carine produced reductions in HR (Figure 2), the effect of
atropine on HR varied (Figure 4). Lower doses of atropine
did not produce any appreciable change in BP or HR, as28:00 29:00 30:00
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Figure 8 Effect of T. violacea (30, 60 and 120 mg/kg) on BP (a) and HR (b) after atropine pre-treatment. PP is pulse pressure. Values are
presented as mean ± SEM. * Indicates statistical significance.
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muscarine chloride has been reported to have similar activ-
ity as acetyl choline, such as reducing BP and HR; although
being more potent [36]. Muscarine reduces BP, while atro-
pine has various effects on BP, from increases [36-38], to
no effect in normotensive Wistar Kyoto (WKY) rats and
SHR [39,40], and decreases at doses of 5–50 mg/kg intra-
venously infused to conscious un-anaesthetized WKY rats
and hypertensive rats (SHR, and Sprague–Dawley rats
made hypertensive by subcutaneous implantation of de-
oxycorticosterone acetate) [41-43]. Atropine has also been
reported to produce vasodilation [28,44].
In rats pre-treated with atropine, the infusion of the T.
violacea (30 mg, 60 mg and 120 mg/kg), led to significant
dose-dependent increases in BP (Figures 7 and 8), as
opposed to dose dependent decreases in the absence of at-
ropine (Figures 5 and 6). Dose-dependent increases in HR
were also observed, which was only significant at theB
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Figure 9 Effect of muscarine (2.5 μg/kg) on BP after atropine pre-treahighest dose given (Figure 8), as opposed to significant
dose-dependent decreases in HR observed in the absence
of atropine (Figure 3). This suggests that the MLE contains
compounds, which act through the muscarinic receptors.
It may also suggest that the MLE, being crude, also con-
tains some substances, which may have BP increasing ef-
fect, which become pronounced when they act on other
receptors in the absence of the action of the MLE on the
muscarinic receptors. Interestingly, a large proportion of
patients with HTN have increased sympathetic activity,
associated with decreased parasympathetic activity [45,46].
In some experiments, the effect of co-infusing atropine
with T. violacea was tested. The BP profile and BP
reductions observed were similar to those seen in the
absence of atropine (results not shown here), which sug-
gests that atropine takes some time before it adequately
blocks the muscarinic receptors. Consequently, the infu-
sion of atropine in this study was done 20 min or moreInfusion ends
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Figure 10 Effect on BP (a) and HR (b) of T. violacea (60 mg/kg) or muscarine (2.5 µg/kg) after atropine pre-treatment. Values are presented as
mean ± SEM. * Indicates statistical significance.
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the same animal, as was done by previous researchers who
tested blockade of muscarinic receptors in other plants
and drugs [30-33]. In experiments that compared the ef-
fect on BP and HR of infusing muscarine (2.5 μg/kg)
(known agonist of the muscarinic receptors) [36], or T.
violacea (60 mg/kg) in rats pre-treated with atropine; the
effect of muscarine on BP and HR (Figures 1 and 2) were
nullified (Figures 9 and 10), while T. violacea increased
SBP and MAP (Figure 10). This experiment further sug-
gests that activation of the muscarinic receptors in the
heart, and consequent bradycardia [47] contributes to the
hypotensive effects of both muscarine and T. violacea.1 8
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Chronic administration of the vehicle (DMSO + NS), T.
violacea (60 mg/kg/day) or captopril (10 mg/kg/day) did
not produce any significant change in the mean body
weight of any of the SHR groups (Figure 10). The SBP
values obtained using the invasive BP measure technique
were significantly lower on day 22 when compared to
the values obtained using the non-invasive tail cuff tech-
nique on day 1, in all groups. These reductions in SBP
were most significant in the captopril group, while the
reduction in SBP in T. violacea group was similar to that
of the control group. Significant reductions in HR also
occurred in the control and captopril groups (result not15 22
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Figure 12 Effect of chronic administration of the vehicle, T. violacea or captopril on BP (a) and HR (b) of male SHR. Values are presented
as mean ± SEM. * Indicates statistical significance.
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or MAP values were only seen in the captopril group
when compared with the control group. There was no
significant difference in final HR among the groups
(Figure 11). The effect of chronic captopril administration
on BP is in line with literature. Captopril is an angiotensin
converting enzyme (ACE) inhibitor, which reduces BP
[48-50]. Reports in literature show that acute captopril ad-
ministration may decrease [51,52], decrease or have no ef-
fect [53] on HR, while chronic captopril administration
may decrease [54] or increase HR [48]. The higher BP600
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Figure 13 Effect of chronic administration of the vehicle, T. violacea o
mean ± SEM. * indicates statistical significance.and HR readings observed with the tail-cuff measure-
ments in the conscious rats earlier in the study, when
compared to the values obtained in anaesthetized rats
with the invasive BP measurement, may be partly due to
sympathetic activation [29,55,56]. This may be second-
ary to mental stress in the conscious rats, despite the
initial two weeks of acclimatization given to all rats used
in the study. Secondly non-invasive BP measurements
are not very reliable [29]. These results suggest that
chronic administration of T. violacea may not reduce
BP or HR in the SHR. This is contrary to the reportedDMSO + NS
Captopril
T. violacea
r captopril on plasma aldosterone levels. Values are presented as
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et al., [24].
The significantly lower plasma levels of aldosterone in
the T. violacea group, when compared with the control
group (Figure 13) agrees with Mackraj, Ramesar et al.,
[24]. However, the significantly lower plasma concentra-
tion in the captopril group when compared to the con-
trol group seen in this study is different from that
observed by Mackraj, Ramesar et al., [24], who did not
observe significantly lower plasma aldosterone level in
the captopril group when compared to the control group
in their study (Figure 13). Aldosterone regulates electro-
lyte, fluid balance and BP homoeostasis [57]. It also
mediates maladaptive tissue remodelling throughout the
CVS and central nervous system (CNS), thereby, wor-
sening the HTN [58-60]. Therefore, a reduction in its
plasma levels is advantageous to the rat.
Conclusion
The results of this study show that the antihypertensive
effects of the crude methanol leaf extract of T. violacea
in male SHR may involve the stimulation of muscarinic
receptors, and reduction in plasma aldosterone levels.
Further studies are required to separate the chemical
compounds present in T. violacea and determine the
pharmacological actions of each of them.
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